On January 7, 2026, AIML subsidiary NeuralCloud Solutions Inc. executed a non-binding commercial term sheet with Lakeshore Cardiology to deploy CardioYield™ powered by MaxYield™ across Lakeshore’s network of 15 cardiac clinics serving more than 12,000 ambulatory patients annually. The agreement outlines a pilot rollout of Holter monitoring services in Q1 2026, targeting the $500 million U.S. market for remote cardiac diagnostics. CardioYield’s AI algorithms are designed to reduce manual review time by up to 60%, improving report turnaround to under 24 hours. Lakeshore will integrate the platform into its existing workflows, with the option to scale to full deployment by year-end pending performance metrics on sensitivity and specificity, which internal tests have placed at 98% and 95%, respectively.

AIML announced the appointment of Erik Suokas as Chief Operating Officer, effective immediately, to accelerate the company’s transition from development to commercial scale. Mr. Suokas, with over 20 years of leadership in medical device commercialization—including scaling annual revenues from $50 million to $200 million at his previous employer—will oversee day-to-day operations, commercial strategy, contract discipline and delivery readiness. His mandate includes aligning revenue projections with product release milestones for AIML’s AI-driven cardiac platform, streamlining cross-functional teams across R&D, sales and customer support, and securing key partnerships to support a projected 150% increase in recurring revenue by Q4 2026.